Unnamed: 0,title,date,stock,sentiment
992261.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,PDLI,positive
992262.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,PDLI,neutral
992263.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,PDLI,positive
992264.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-18 07:34:00-04:00,PDLI,neutral
992265.0,Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.,2020-05-14 11:18:00-04:00,PDLI,negative
992266.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-14 07:40:00-04:00,PDLI,neutral
992267.0,"PDL BioPharma Q1 EPS $(0.26) vs $0.05 In Same Qtr. Last Year, Sales $5.995M Down From $6.696M YoY",2020-05-07 16:46:00-04:00,PDLI,neutral
992268.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,PDLI,negative
992269.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,PDLI,neutral
992270.0,5 Stocks Moving In Wednesday's After-Hours Session,2020-03-11 16:48:00-04:00,PDLI,neutral
992271.0,PDL BioPharma shares are trading lower after the company reported Q4 earnings results. The company announced plans to dissolve the company by the end of 2020.,2020-03-11 16:16:00-04:00,PDLI,neutral
992272.0,PDL BioPharma Q4 EPS $(0.48) Does Not Compare To $0.05 Estimate,2020-03-11 16:11:00-04:00,PDLI,neutral
992273.0,PDL BioPharma Board Approves Plan To Dissolve Co. By End Of 2020,2020-03-11 16:10:00-04:00,PDLI,positive
992274.0,PDL BioPharma Announces Appointment of Edward A. Imbrogno as Vice President and Chief Financial Officer,2020-03-09 16:12:00-04:00,PDLI,neutral
992275.0,PDL BioPharma Enters Into Cooperation Agreement With Engine Capital; Terms Not Disclosed,2020-02-28 08:04:00-05:00,PDLI,positive
992276.0,PDL BioPharma Adds $75M To Buyback Of Common Stock And Convertible Notes,2019-12-16 08:39:00-05:00,PDLI,neutral
992277.0,"SevenSaoi Capital Issues Release On PDL BioPharma Expressing Support To Board, Mgmt. Team Following Recent Steps",2019-12-10 15:12:00-05:00,PDLI,positive
992278.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,PDLI,neutral
992279.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,PDLI,neutral
992280.0,PDL BioPharma shares are trading higher after the company announced the completion of its strategic review. It will halt the execution of its growth strategy and focus on returning proceeds from asset sales to shareholders. The company also announced a $200 million buyback.,2019-12-09 09:03:00-05:00,PDLI,positive
992281.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,PDLI,neutral
992282.0,"PDL BioPharma Reviews Strategic Review, Will Halt Execution of its Growth Strategy and Focus on Returning Proceeds from Asset Sales to Shareholders, Announces $200M Buyback",2019-12-09 08:03:00-05:00,PDLI,positive
992283.0,"PDL BioPharma Q3 EPS $(0.16) Down From $0.18 YoY, Sales $44.165M Beat $33.86M Estimate",2019-11-06 17:02:00-05:00,PDLI,neutral
992284.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,PDLI,positive
992285.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,PDLI,positive
992286.0,41 Biggest Movers From Yesterday,2019-10-24 04:25:00-04:00,PDLI,neutral
992287.0,Mid-Morning Market Update: Energy Shares Rise By 1.3%; ConocoPhilips Shares Move Higher,2019-10-23 10:44:00-04:00,PDLI,positive
992288.0,PDL BioPharma shares are trading higher after Engine Capital issued a letter to the board of the PDL BioPharma encouraging the company to cease investment activities and commence a review of strategic alternatives.,2019-10-23 09:51:00-04:00,PDLI,positive
992289.0,14 Stocks Moving in Wednesday's Pre-Market Session,2019-10-23 08:51:00-04:00,PDLI,neutral
992290.0,"Engine Capital Issues Letter To Board Of PDL BioPharma Encouraging Co. To 'Cease Its Investment Activities And Commence A Review Of Strategic Alternatives, Including A Possible Sale Or Liquidation Of The Company",2019-10-23 07:19:00-04:00,PDLI,positive
992291.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-03 13:03:00-04:00,PDLI,negative
992292.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,PDLI,negative
992293.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,PDLI,negative
992294.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,PDLI,positive
992295.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,PDLI,negative
992296.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,PDLI,positive
992297.0,56 Biggest Movers From Friday,2019-09-16 05:29:00-04:00,PDLI,neutral
992298.0,Stocks That Hit 52-Week Lows On Friday,2019-09-13 15:08:00-04:00,PDLI,negative
992299.0,35 Stocks Moving In Friday's Mid-Day Session,2019-09-13 12:56:00-04:00,PDLI,neutral
992300.0,PDL BioPharma Receives Favorable Decision in Wellstat Diagnostics Litigation,2019-09-12 04:17:00-04:00,PDLI,positive
992301.0,PDL BioPharma Q2 Adj EPS $0.11 Beats $0.04 Estimate,2019-08-07 16:42:00-04:00,PDLI,neutral
992302.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,PDLI,neutral
992303.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,PDLI,neutral
992304.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,PDLI,neutral
992305.0,PDL BioPharma Announces Departure Of CFO,2019-06-25 16:07:00-04:00,PDLI,neutral
992306.0,"PDL BioPharma Q1 EPS $0.05 Misses $0.08 Estimate, Sales $38.913M Beat $34.68M Estimate",2019-05-09 16:58:00-04:00,PDLI,negative
992307.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,PDLI,neutral
992308.0,PDL BioPharma Highlights Securities Purchase Deal With Evofem Biosciences For Up To $60M Investment Through Private Placement Of Securities,2019-04-11 10:26:00-04:00,PDLI,positive
992309.0,"Evofem Biosciences Reports Financing Deal For Up To $80M, Closes First Tranche Of Strategic Investment From PDL BioPharma",2019-04-11 10:20:00-04:00,PDLI,neutral
992310.0,"The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing",2019-04-09 08:10:00-04:00,PDLI,neutral
992311.0,"PDL BioPharma Q4 EPS $0.11 Beats $0.08 Estimate, Sales $45.119M Miss $46.08M Estimate",2019-03-14 16:50:00-04:00,PDLI,negative
992312.0,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",2019-03-14 07:47:00-04:00,PDLI,neutral
992313.0,"Earnings Scheduled For March 14, 2019",2019-03-14 04:14:00-04:00,PDLI,neutral
992314.0,PDL BioPharma Announces Launch Of Authorized Generic Of Tekturna In Partnership With Prasco Laboratories,2019-03-04 16:15:00-05:00,PDLI,neutral
992315.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,PDLI,positive
992316.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,PDLI,neutral
992317.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,PDLI,positive
992318.0,"The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering",2019-02-20 07:34:00-05:00,PDLI,negative
992319.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Jan. 10, 2019",2019-01-11 13:04:00-05:00,PDLI,neutral
992320.0,"Stocks Which Set New 52-Week High Yesterday, Tues. Jan. 8, 2019",2019-01-09 10:57:00-05:00,PDLI,neutral
992321.0,"The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study",2019-01-09 07:39:00-05:00,PDLI,negative
992322.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,PDLI,neutral
992323.0,70 Stocks Moving In Wednesday's Mid-Day Session,2018-11-07 12:52:00-05:00,PDLI,neutral
992324.0,Mid-Morning Market Update: Markets Open Higher; Humana Earnings Beat Expectations,2018-11-07 10:29:00-05:00,PDLI,neutral
992325.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,PDLI,negative
992326.0,"PDL BioPharma Q3 EPS $0.18 Beats $0.07 Estimate, Sales $67.9M Beat $50.6M Estimate",2018-11-06 16:17:00-05:00,PDLI,neutral
992327.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-10-09 08:19:00-04:00,PDLI,neutral
992328.0,PDL BioPharma Announces $100M Buyback,2018-09-24 09:02:00-04:00,PDLI,neutral
992329.0,"PDL BioPharma Stakeholder, SevenSaoi Capital, Delivers Letter To Board Expressing 'Serious Concerns' Regarding Co.'s Acquisition Strategy; Says Board Must Pursue Alternative Capital Allocation Strategies, Including A 'Significant' Share Repurchase",2018-09-20 08:36:00-04:00,PDLI,positive
992330.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,PDLI,negative
992331.0,"PDL BioPharma Q2 GAAP EPS $(0.76) May Not Compare To $0.06 Estimate, Sales $46.6M Beat $44.66M Estimate",2018-08-08 16:15:00-04:00,PDLI,neutral
992332.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,PDLI,positive
992333.0,PDL BioPharma Acquires Depomed's Remaining 50% Interest In Royalties And Milestones On Type 2 Diabetes Products,2018-08-02 16:36:00-04:00,PDLI,positive
992334.0,"PDL Biopharma Says on June 8, Co's Unit Entered into Settlement Agreement With Anchen Pharmaceuticals and its Affiliates to Resolve Patent Litigation on Anchen's ANDA for FDA Approval for Generic Version of Tekturna Product",2018-06-12 06:15:00-04:00,PDLI,positive
992335.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,PDLI,neutral
992336.0,7 Stocks Moving In Wednesday's After-Hours Session,2018-05-09 17:16:00-04:00,PDLI,neutral
992337.0,"PDL BioPharma Q1 EPS $0.01 Misses $0.06 Estimate, Sales $38.52M Miss $50.4M Estimate",2018-05-09 16:05:00-04:00,PDLI,negative
992338.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,PDLI,neutral
992339.0,Mid-Afternoon Market Update: Crude Oil Up Over 3%; PDL BioPharma Shares Spike Higher,2018-03-09 14:32:00-05:00,PDLI,negative
992340.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,PDLI,neutral
992341.0,Mid-Day Market Update: Dow Rises Over 250 Points; AutoWeb Shares Plunge,2018-03-09 12:04:00-05:00,PDLI,positive
992342.0,Mid-Morning Market Update: Markets Open Higher; Finisar Earnings Miss Views,2018-03-09 10:13:00-05:00,PDLI,negative
992343.0,26 Stocks Moving In Friday's Pre-Market Session,2018-03-09 08:07:00-05:00,PDLI,neutral
992344.0,"8 Stocks To Watch For March 9, 2018",2018-03-09 04:32:00-05:00,PDLI,neutral
992345.0,10 Stocks Moving In Thursday's After-Hours Session,2018-03-08 18:05:00-05:00,PDLI,neutral
992346.0,"PDL BioPharma Shares Up 13.2% After Hours As Co. Reported Q4 EPS $0.15 vs $0.03 Est., Sales $68.04M vs $45.3M Est.",2018-03-08 16:21:00-05:00,PDLI,positive
992347.0,"Earnings Scheduled For March 8, 2018",2018-03-08 04:00:00-05:00,PDLI,neutral
992348.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,PDLI,neutral
992349.0,"Neos Therapeutics Reiterates Confidence in Strategic Plan, Value Creation Opportunities",2018-02-20 09:58:00-05:00,PDLI,positive
992350.0,"PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos, Says It Doesn't Plan To Make Any Further Proposals",2018-02-20 07:11:00-05:00,PDLI,positive
992351.0,PDL BioPharma's Noden Pharma Announces FDA Approval of Tekturna Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older,2017-11-15 10:41:00-05:00,PDLI,positive
992352.0,PDL BioPharma's Proposal to Acquire Neos Therapeutics for $10.25/Share Cash Expires Today; PDL Urges Neos to Provide Update on Sale Process,2017-11-08 08:03:00-05:00,PDLI,neutral
992353.0,"PDL BioPharma Reports Q3 Adj. EPS $0.14 vs $0.13 Est., Sales $62.749M vs $61.86M Est.",2017-11-02 17:06:00-04:00,PDLI,neutral
992354.0,"Wall Street's M&A Chatter From October 31: Neos Therapeutics, Rockwell Automation-Emerson Electric, Charter",2017-11-01 07:38:00-04:00,PDLI,neutral
992355.0,"Reuters Reports Neos Therapeutics Rejected A 4th Takeover Offer By PDL Biopharma, Will Consider Offers From Other Potential Buyers According To Sources",2017-10-31 15:10:00-04:00,PDLI,negative
992356.0,"UPDATE: PDL Says Disappointed With Neos Response, Highlights 'PDL has a number of investment opportunities before it, of which Neos is only one,' Reiterates Proposal Remains Outstanding Through Nov. 8, 2017",2017-10-30 16:40:00-04:00,PDLI,positive
992357.0,PDL BioPharma Issues Release Offering Response To Neos Therapeutics' Rejection Of Co.'s Offer,2017-10-30 16:39:00-04:00,PDLI,negative
992358.0,Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma To Acquire All Shares of Neos For $10.25/Share,2017-10-30 08:33:00-04:00,PDLI,negative
992359.0,PDL BioPharma Reports Settlement Agreement with Valeant; Valeant To Pay One-Time Lump-Sum Payment of $13M,2017-10-30 07:03:00-04:00,PDLI,positive
992360.0,40 Biggest Movers From Yesterday,2017-10-27 04:57:00-04:00,PDLI,neutral
992361.0,PDL's Offer For Neos Therapeutics Could Be Too Low,2017-10-26 13:45:00-04:00,PDLI,negative
992362.0,"Cowen Comments On PDL Bid For NEOS: Says 'Offer Looks Too Low; We Think
Closer To $20 Per Share Is Reasonable'; Maintains Outperform Rating, $20 Price Target",2017-10-26 10:42:00-04:00,PDLI,neutral
992363.0,"Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma, Neos Board Will Respond To PDL Proposal Received Today In Due Course",2017-10-26 10:04:00-04:00,PDLI,neutral
992364.0,Neos Therapeutics Shares Halted To Announce PDLI BioPharma Has Proposed To Purchase Co. At $10.25/Share In Cash,2017-10-26 08:30:00-04:00,PDLI,positive
992365.0,PDL BioPharma Announces $25M Buyback,2017-09-25 07:00:00-04:00,PDLI,neutral
992366.0,PDL BioPharma Names Dominique Monnet Pres,2017-09-11 16:04:00-04:00,PDLI,neutral
992367.0,20 Biggest Mid-Day Gainers For Friday,2017-08-04 12:41:00-04:00,PDLI,neutral
992368.0,"PDL BioPharma Reports Q2 EPS $0.39 vs $0.03 In Same Qtr. Last Year, Sales $143.8M vs $21.047M YoY",2017-08-03 16:11:00-04:00,PDLI,neutral
992369.0,"PDL Biopharma Says Announced That Its Subsidiary, Noden Pharma DAC Received Paragraph IV Notice Letter That Anchen Pharmaceuticals Submitted Abbreviated NDA to FDA",2017-06-05 06:11:00-04:00,PDLI,neutral
992370.0,"PDL BioPharma Reports Q1 EPS $0.04 vs $0.05 Est., Sales $45.4M vs $50.23M Est.",2017-05-03 17:11:00-04:00,PDLI,neutral
992371.0,PDL BioPharma to Receive $19.5M From Merck to Settle Patent Lawsuit,2017-04-24 07:04:00-04:00,PDLI,negative
992372.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,PDLI,neutral
992373.0,"PDL BioPharma Reports Q4 Adj. Loss $8.6M, GAAP EPS $(0.06), Sales $66.5M vs $56.4M Est.",2017-03-01 16:25:00-05:00,PDLI,negative
992374.0,20 Biggest Mid-Day Gainers For Wednesday,2017-03-01 12:46:00-05:00,PDLI,neutral
992375.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-03-01 08:19:00-05:00,PDLI,neutral
992376.0,PDL BioPharma Reports $30M Buyback Plan,2017-03-01 07:22:00-05:00,PDLI,neutral
992377.0,"PiperJaffray Reinstates Overweight on PDL BioPharma, Announces $4 Target",2016-12-22 08:11:00-05:00,PDLI,negative
992378.0,LENSAR Announces Strategic Restructure in Partnership with PDL BioPharma,2016-12-19 09:54:00-05:00,PDLI,neutral
992379.0,Stocks Hitting 52-Week Lows,2016-12-06 10:24:00-05:00,PDLI,negative
992380.0,Stocks Hitting 52-Week Lows,2016-11-29 10:22:00-05:00,PDLI,negative
992381.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-23 13:06:00-05:00,PDLI,negative
992382.0,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",2016-11-23 10:02:00-05:00,PDLI,neutral
992383.0,Mid-Afternoon Market Update: StemCells Climbs On Asset Purchase Agreement; Endologix Shares Drop,2016-11-16 14:30:00-05:00,PDLI,positive
992384.0,12 Biggest Mid-Day Losers For Wednesday,2016-11-16 12:48:00-05:00,PDLI,negative
992385.0,Mid-Day Market Update: Dow Falls 75 Points; Shipping Stocks Spike Higher,2016-11-16 12:04:00-05:00,PDLI,neutral
992386.0,Mid-Morning Market Update: Markets Mostly Lower; Target Q3 Profit Beats Views,2016-11-16 10:04:00-05:00,PDLI,positive
992387.0,"PDL BioPharma Reports Q3 EPS $0.08 vs. Est. $0.08, Rev. $53.63M vs. Est. $50.6M",2016-11-03 17:11:00-04:00,PDLI,neutral
992388.0,Option Alert: PDLI Feb 17 $3 Calls at the Bid: 5000 @ 0.401 vs. Open Interest 422,2016-09-07 11:04:00-04:00,PDLI,positive
992389.0,PDL BioPharma Gets $57.4M For Termination of Credit Agreement With Paradigm Spine,2016-08-29 07:03:00-04:00,PDLI,positive
992390.0,18 Biggest Mid-Day Losers For Friday,2016-08-05 13:14:00-04:00,PDLI,negative
992391.0,"PDL BioPharma Reports Q2 EPS $0.09 vs. Est. $0.08, Rev. $21M vs. Est. $33M",2016-08-04 17:34:00-04:00,PDLI,neutral
992392.0,PDL BioPharma Announces Elimination of Quarterly Cash Dividend,2016-08-04 16:54:00-04:00,PDLI,neutral
992393.0,PDL BioPharma Reports ~$107M Commitment to Equity Investment in Noden Pharma for Purchase of Tekturna,2016-05-24 16:10:00-04:00,PDLI,positive
992394.0,"PDL BioPharma Reports Q1 Adj. EPS $0.52 vs $0.50 Est., Sales $103.1M",2016-05-04 17:26:00-04:00,PDLI,neutral
992395.0,"PDL BioPharma Reports Q4 EPS $0.61 vs $0.54 Est., Sales $178.1M vs $149.2M Est.",2016-02-22 16:03:00-05:00,PDLI,neutral
992396.0,"Alphabet, Matel & PDL BioPharma Are Moving After-Hours",2016-02-01 16:38:00-05:00,PDLI,neutral
992397.0,Why These Four Stocks Are Moving In Wednesday's After-Hours Session,2015-12-30 16:41:00-05:00,PDLI,neutral
992398.0,PDL BioPharma Discloses Receipts From Income Generating Assets,2015-12-02 09:03:00-05:00,PDLI,positive
992399.0,"PDL BioPharma Announces Developments Related to LENSAR Debt Investment, Will Receive ~$12.5 In Alphaeon Common Stock",2015-11-16 14:56:00-05:00,PDLI,negative
992400.0,PDL BioPharma Announces Developments Related to LENSAR Debt Investment,2015-11-16 14:56:00-05:00,PDLI,negative
992401.0,"UPDATE: PDL Biopharma Release ""Recieved no communication from Valeant or Depomed as to why payments and reporting were late""",2015-11-06 09:06:00-05:00,PDLI,negative
992402.0,PDL BioPharma Provides Additional Information Regarding Acquired Diabetes Royalty Rights,2015-11-06 09:02:00-05:00,PDLI,neutral
992403.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,PDLI,positive
992404.0,"Dyax, Juno Therapeutics Soar Following Biotech Index Rebalance",2015-10-15 13:40:00-04:00,PDLI,neutral
992405.0,"NYSE Arca Biotech Index Fund Announced At 11:45 EDT That It Would Be Rebalancing, Will Add DYAX And JUNO and Remove EXAS and PDLI",2015-10-15 13:03:00-04:00,PDLI,neutral
992406.0,"Hearing Dyax Inc And Juno Therapeutics Being Added To First Trust NYSE ARca Biotechnology Index Fund; PDL Biopharama And Exact Sciences To be Removed, Effective At The Close On Friday Oct 16",2015-10-15 12:34:00-04:00,PDLI,positive
992408.0,PDL BioPharma Reports Received ~$21.4M Related to Termination of Structured Financing Deal with Avinger,2015-09-23 07:01:00-04:00,PDLI,neutral
992409.0,Morning Market Gainers,2015-09-21 09:42:00-04:00,PDLI,neutral
992410.0,Benzinga's Top #PreMarket Gainers,2015-09-21 08:15:00-04:00,PDLI,positive
992411.0,"PDL BioPharma Announces Acquisition of Portion of AcelRx Pharma, Royalties, Expected Milestones from Zalviso for $65M",2015-09-21 07:01:00-04:00,PDLI,neutral
992412.0,Paul Edick Joins PDL BioPharma's Board of Directors,2015-09-08 07:04:00-04:00,PDLI,neutral
992413.0,"PDL Biopharma CFO Garcia Buys 20,000 Shares @$5.83/Share -Form 4",2015-08-17 07:20:00-04:00,PDLI,positive
992414.0,"PDL BioPharma Reports Q2 EPS $0.47 vs. Est. $0.52, Rev. $138.066M vs. Est. $137.75M",2015-08-05 16:55:00-04:00,PDLI,neutral
992415.0,ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma,2015-07-29 07:35:00-04:00,PDLI,neutral
992416.0,PDL BioPharma Will Provide $40M Financing To CareView Communications,2015-06-29 17:04:00-04:00,PDLI,neutral
992418.0,Stocks Hitting 52-Week Lows,2015-06-09 10:20:00-04:00,PDLI,negative
992419.0,Option Alert: PDL Biopharma Nov $7 Call;  1382 Contract Trade at Ask @$0.65; Now $6.89,2015-04-27 12:29:00-04:00,PDLI,positive
992420.0,8-K from PDL BioPharma Shows Chief Accounting Officer David Montez Resigned,2015-04-23 17:03:00-04:00,PDLI,negative
992422.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Operating Margin,2015-03-30 04:59:00-04:00,PDLI,positive
992423.0,"PDL Biopharma Announces Dismissal of Third, Final Holder Suit",2015-03-03 07:04:00-05:00,PDLI,neutral
992424.0,Stocks Hitting 52-Week Lows,2015-02-24 10:15:00-05:00,PDLI,negative
992425.0,Morning Market Losers,2015-02-24 09:50:00-05:00,PDLI,negative
992426.0,"Tuesday's #PreMarket Movers: Home Depot, SunPower Trending Higher",2015-02-24 08:54:00-05:00,PDLI,neutral
992427.0,Benzinga's Top #PreMarket Losers,2015-02-24 08:26:00-05:00,PDLI,negative
992428.0,"UPDATE: PDL Biopharma Misses Q4 Views, Shares Decline After Hours",2015-02-23 18:04:00-05:00,PDLI,positive
992429.0,"Monday After-Hours Movers: Five9, Stifel Trending Up",2015-02-23 17:21:00-05:00,PDLI,neutral
992430.0,"PDL Biopharma Reports Q4 EPS $0.32 Vs Est $0.57 May Not Compare, Sales $117.1M Vs Est $158.15M",2015-02-23 16:10:00-05:00,PDLI,neutral
992431.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2015-02-03 04:32:00-05:00,PDLI,negative
992432.0,US Stock Futures Mostly Flat Ahead Of Housing Data,2014-11-18 07:11:00-05:00,PDLI,neutral
992433.0,PDL BioPharma Announces Successful Conclusion Of Debt Financing Agreement With Durata Therapeutics,2014-11-18 07:03:00-05:00,PDLI,positive
992434.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,PDLI,neutral
992435.0,PDL BioPharma Receices Additional $30.3M In Interest Payments,2014-11-14 07:04:00-05:00,PDLI,positive
992436.0,"PDL BioPharma, Inc. Reports Q3 EPS of $0.61 vs $0.56 Est",2014-11-10 16:03:00-05:00,PDLI,neutral
992437.0,PDL BioPharma Acquires Portion Of The University of Michigan's Royalty Interest in Genzyme's Cerdelga For $65.6M ,2014-11-06 16:16:00-05:00,PDLI,positive
992438.0,5 Healthcare Stocks With The Highest Operating Margin,2014-09-23 09:23:00-04:00,PDLI,neutral
992439.0,"PDL BioPharma Offers Statement on Resignation of Ernst, Young as Auditor",2014-09-17 17:57:00-04:00,PDLI,negative
992440.0,"Midday Losers From September 17 - Rackspace Hosting, Inc., Owens-Illinois Inc And More",2014-09-17 13:49:00-04:00,PDLI,negative
992441.0,Morning Market Losers ,2014-09-17 09:48:00-04:00,PDLI,negative
992442.0,Benzinga's Top #PreMarket Losers,2014-09-17 08:10:00-04:00,PDLI,negative
992443.0,PDL BioPharma Inc: The Biotech Stock That Pays A Nice Dividend,2014-09-15 12:17:00-04:00,PDLI,positive
992444.0,"PDL BioPharma, Inc. Sees Q3 Sales $165.0M vs $149.25M Est",2014-09-09 16:02:00-04:00,PDLI,neutral
992445.0,5 Healthcare Stocks With The Lowest PEG Ratio,2014-09-08 09:26:00-04:00,PDLI,negative
992446.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Operating Margin,2014-08-21 04:57:00-04:00,PDLI,positive
992447.0,Morning Market Movers ,2014-08-19 09:40:00-04:00,PDLI,neutral
992448.0,Benzinga's Top #PreMarket Gainers,2014-08-19 08:15:00-04:00,PDLI,positive
992449.0,"PDL BioPharma, Inc. Reports Q2 EPS of $0.52 vs $0.46 Est; Revenue of $162.80M vs $134.07M Est",2014-08-18 16:04:00-04:00,PDLI,neutral
992450.0,"Earnings Scheduled For August 11, 2014",2014-08-11 05:30:00-04:00,PDLI,neutral
992451.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2014-07-10 04:51:00-04:00,PDLI,negative
992452.0,330K Share Block Trade in PDL Biopharma @4:20 PM ET,2014-06-12 15:22:00-04:00,PDLI,negative
992453.0,"PDL BioPharma, Inc. Sees Q2 Sales $140.0M vs $134.0M Est",2014-06-10 16:08:00-04:00,PDLI,neutral
992454.0,"Ex-Dividends For June 3, 2014",2014-06-03 09:05:00-04:00,PDLI,neutral
992455.0,"PDL BioPharma, Inc. Reports Q1 EPS of $0.44 vs $0.45 Est; Revenue of $139.70M vs $130.93M Est",2014-05-12 16:06:00-04:00,PDLI,neutral
992456.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2014-04-02 04:29:00-04:00,PDLI,negative
992457.0,"PDL BioPharma, Inc. Sees Q1 Sales $133.0M vs $134.40M Est",2014-03-11 16:17:00-04:00,PDLI,neutral
992458.0,"PDL BioPharma Reports Conversion Rate Adjustments for Convertible Notes, 3.75% Notes at ~$6.15/Share, 2.875% Notes at ~$5.38/Share",2014-03-04 16:05:00-05:00,PDLI,neutral
992459.0,"PDL BioPharma, Inc. Reports Q4 EPS of $0.39 vs $0.43 Est; Revenue of $110.10M vs $115.22M Est",2014-03-03 16:03:00-05:00,PDLI,neutral
992460.0,"PDL BioPharma, Paradigm Spine Complete $75M Financing Transaction ",2014-02-18 07:11:00-05:00,PDLI,neutral
992461.0,"PDL Biopharma Announces Entry Into Exchange, Buy Pacts with Certain Holders of Convertible Senior Notes, Will Issue 20.3M Shares, Pay $34.2M",2014-02-07 07:03:00-05:00,PDLI,positive
992462.0,PDL BioPharma Announces Settlement with Genentech and Roche ,2014-02-03 07:13:00-05:00,PDLI,neutral
992463.0,"PDL BioPharma, Inc. Sees Q4 Sales $109.0M vs $107.70M Est",2013-12-10 16:04:00-05:00,PDLI,neutral
992464.0,"PDL BioPharma, Inc. Reports Q3 EPS of $0.36 vs $0.37 Est; Revenue of $97.30M vs $97.09M Est",2013-11-06 16:36:00-05:00,PDLI,neutral
992465.0,PDL Biopharma Issues $70M in Financing to Durata Therapeutics,2013-11-06 07:34:00-05:00,PDLI,neutral
992466.0,Depomed Call: 'We Will Continue to Stay Focused on Growth-Oriented Acquisition',2013-10-21 17:23:00-04:00,PDLI,positive
992467.0,Depomed Call: 'Our First Priority is to Look for Marketed and Late Stage Products',2013-10-21 17:14:00-04:00,PDLI,neutral
992468.0,Depomed Call: 'We've Talked to Quite a Few People About Our Royalties',2013-10-21 17:12:00-04:00,PDLI,neutral
992469.0,Depomed Call: 'We have Cash on Hand of Over $320M',2013-10-21 17:11:00-04:00,PDLI,positive
992470.0,"Depomed Will Host a Conference Call at 5PM EDT to Discuss Sale of Royalties, Milestones",2013-10-21 16:29:00-04:00,PDLI,neutral
992471.0,LENSAR Secures $87M in Financing to Support Market Expansion of Its Laser Cataract Surgery System ,2013-10-02 08:04:00-04:00,PDLI,positive
992472.0,PDL BioPharma to Provide Up to $60M of Debt Financing to LENSAR ,2013-10-02 07:04:00-04:00,PDLI,negative
992473.0,"PDL BioPharma, Inc. Sees Q3 Sales $97.0M vs $97.90M Est",2013-09-09 07:15:00-04:00,PDLI,neutral
992474.0,13D Filing from PDL Biopharma Shows 6.81% Stake in Axogen,2013-08-19 17:28:00-04:00,PDLI,neutral
992475.0,"PDL BioPharma, Inc. Reports Q2 EPS of $0.62 vs $0.54 Est; Revenue of $143.60M vs $138.20M Est",2013-08-08 16:02:00-04:00,PDLI,neutral
992476.0,PDL Biopharma Files Automatic Debt Shelf,2013-06-21 17:17:00-04:00,PDLI,negative
992477.0,PDL BioPharma Reports Q2 Royalty Sales Guidance $143M,2013-06-11 16:03:00-04:00,PDLI,neutral
992478.0,PDL Files for Arbitration Against Genentech Based on Underpayment of Royalties,2013-06-11 07:17:00-04:00,PDLI,neutral
992479.0,PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes,2013-06-03 16:02:00-04:00,PDLI,neutral
992480.0,UPDATE: Piper Jaffray Initiates PDL BioPharma at Neutral on Strong Royalties,2013-05-15 06:32:00-04:00,PDLI,positive
992481.0,"Piper Jaffray Initiates Coverage on PDL BioPharma, Inc. at Neutral, Announces $8.50 PT",2013-05-14 16:10:00-04:00,PDLI,neutral
992482.0,"PDL BioPharma, Inc. Reports Q1 EPS of $0.36 vs $0.35 Est; Revenue of $91.80M vs $91.69M Est",2013-05-09 16:48:00-04:00,PDLI,neutral
992483.0,PDL BioPharma Appoints Peter Garcia as Chief Financial Officer,2013-04-30 16:03:00-04:00,PDLI,neutral
992484.0,PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger,2013-04-22 12:52:00-04:00,PDLI,neutral
992485.0,"Avinger, PDL BioPharma Close Mezzanine Financing",2013-04-22 07:16:00-04:00,PDLI,neutral
992486.0,"Avinger, PDL Biopharma Close on $40M Structured Financing and Royalty Transaction",2013-04-22 07:07:00-04:00,PDLI,neutral
992487.0,"PDL BioPharma Issues Q1 Royalty Outlook, Says Tysabri Sales Rose 16% in Q4",2013-03-11 07:37:00-04:00,PDLI,neutral
992488.0,UPDATE: J.P. Morgan Lowers PT on PDL BioPharma on Model Update,2013-03-06 08:11:00-05:00,PDLI,negative
992489.0,"JP Morgan Maintains Neutral on PDL BioPharma, Inc., Lowers PT to $6.00",2013-03-05 16:33:00-05:00,PDLI,positive
992490.0,"PDL BioPharma, Inc. Reports Q4 EPS of $0.34 vs $0.32 Est; Revenue of $86.0M vs $86.08M Est",2013-03-01 16:03:00-05:00,PDLI,neutral
992491.0,"Earnings Scheduled For March 1, 2013",2013-03-01 04:55:00-05:00,PDLI,neutral
992492.0,"Mid-Afternoon Market Update: Markets Mixed, Given Drops After Company Abandons Sale",2013-01-15 15:34:00-05:00,PDLI,negative
992493.0,UPDATE: Credit Suisse Downgrades PDL Biopharma to Underperform on Valuation  ,2013-01-15 12:32:00-05:00,PDLI,positive
992494.0,Mid-Morning Market Update: Dell Continues to Rise While Lulu Lemon Takes a Hit,2013-01-15 10:33:00-05:00,PDLI,neutral
992495.0,"Credit Suisse Downgrades PDL BioPharma, Inc. to Underperform, Lowers PT to $6.00",2013-01-15 08:34:00-05:00,PDLI,positive
992496.0,"Janney Capital Initiates Coverage on PDL BioPharma, Inc. at Neutral, Announces $7.00 PT",2013-01-02 17:12:00-05:00,PDLI,neutral
992497.0,"PDL Biopharma Sees Q4 Royalty Sales of $86M, Sees FY Sales $374M vs $368.25M Est",2012-12-06 16:13:00-05:00,PDLI,neutral
992498.0,PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes,2012-12-05 16:11:00-05:00,PDLI,neutral
992499.0,PDL BioPharma Announces Convertible Notes Adjustments,2012-12-05 16:04:00-05:00,PDLI,neutral
992500.0,PDL Biopharma Reports CFO Bruce Tomlinson Resigning,2012-12-03 16:03:00-05:00,PDLI,negative
992501.0,UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions  ,2012-11-13 13:40:00-05:00,PDLI,positive
992502.0,"Credit Suisse Initiates Coverage on PDL BioPharma at Neutral, Announces PT of $6.50",2012-11-12 16:25:00-05:00,PDLI,positive
992503.0,PDL BioPharma Reports,2012-11-07 17:00:00-05:00,PDLI,neutral
992504.0,PDL BioPharma Reports Q3 EPS $0.32 vs $0.30 Est; Revenues $85.2M vs $85.03M Est,2012-11-05 16:22:00-05:00,PDLI,neutral
992505.0,PDL BioPharma Reports Q2 EPS $0.53 vs $0.49 Est; Revenues $125.9M vs $125.14M Est,2012-08-02 16:44:00-04:00,PDLI,neutral
992506.0,Earnings Scheduled For July 13,2012-07-13 03:01:00-04:00,PDLI,neutral
992507.0,PDL to Receive Royalties on Sales of Genentech's Pertuzumab ,2012-06-19 07:00:00-04:00,PDLI,neutral
992508.0,5 Healthcare Stocks With The Highest Operating Margin,2012-06-18 07:25:00-04:00,PDLI,neutral
992509.0,PDL BioPharma Provides Second Quarter 2012 Royalty Revenue Guidance of $125 Million vs $122M Est,2012-06-13 16:05:00-04:00,PDLI,neutral
992510.0,Three Keys to Finding Good Dividend Stocks,2012-06-06 12:37:00-04:00,PDLI,positive
992511.0,PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes ,2012-06-05 07:02:00-04:00,PDLI,neutral
992512.0,PDL BioPharma Appoints Bruce Tomlinson as Chief Financial Officer ,2012-04-26 16:03:00-04:00,PDLI,neutral
992513.0,PDL BioPharma Provides First Quarter 2012 Royalty Revenue Guidance of $77M,2012-03-08 16:02:00-05:00,PDLI,neutral
992514.0,PDL BioPharma Reports Q4 EPS $0.24 vs $0.24 Est; Revenues $72.8M vs $72.85M Est	 				,2012-02-23 16:11:00-05:00,PDLI,neutral
992515.0,"PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015",2012-02-02 17:08:00-05:00,PDLI,neutral
992516.0,PDL BioPharma Announces Settlement and Final Results of its Exchange Offer  ,2012-01-06 07:23:00-05:00,PDLI,neutral
992517.0,Market Roundup,2011-12-19 10:17:00-05:00,PDLI,neutral
992518.0,Benzinga's Top Pre-Market Losers,2011-12-19 08:24:00-05:00,PDLI,negative
992519.0,PDL BioPharma Shares Down In Pre-Market On Downbeat Revenue Forecast,2011-12-19 08:05:00-05:00,PDLI,positive
992520.0,PDL BioPharma Provides Q4 Revenue Guidance of $72M vs $82.46M ,2011-12-19 07:01:00-05:00,PDLI,neutral
992521.0,Market Update,2011-12-12 09:31:00-05:00,PDLI,neutral
992522.0,PDL BioPharma Announces Departure of Chief Financial Officer,2011-12-12 07:30:00-05:00,PDLI,neutral
992523.0,PDL BioPharma Corrects Its Adjusted Conversion Rates for Its Convertible Notes ,2011-12-12 07:01:00-05:00,PDLI,neutral
992524.0,PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes ,2011-12-07 07:00:00-05:00,PDLI,neutral
992525.0,5 Small-Cap NASDAQ Stocks with Amazing Dividends,2011-11-15 14:48:00-05:00,PDLI,positive
992526.0,"PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015 ",2011-11-15 07:03:00-05:00,PDLI,neutral
992527.0,PDL BioPharma Reports Q3 Revenues $83.80M vs $82.85M Est			,2011-11-09 16:01:00-05:00,PDLI,neutral
992528.0,PDL BioPharma Retains Franklin Berger and Dr. Evan Bedil as Advisors to Assist with Implementation of Royalty Acquisition Strategy ,2011-10-19 07:02:00-04:00,PDLI,neutral
992529.0,PDL BioPharma Issues Downbeat Q3 Revenue Forecast,2011-09-08 07:58:00-04:00,PDLI,neutral
992530.0,PDL BioPharma Sees Q3 Revenue of $83M vs $86M Year Ago,2011-09-08 07:05:00-04:00,PDLI,neutral
992531.0,PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes,2011-09-07 07:02:00-04:00,PDLI,neutral
992532.0,PDL BioPharma Q2 EPS of $0.038 vs. $0.40 Est; Revenues $122.1M vs. $123.25M		,2011-07-27 16:01:00-04:00,PDLI,neutral
992533.0,Calls Purchased on PDL BioPharma,2011-07-11 12:48:00-04:00,PDLI,neutral
992534.0,PDL BioPharma Trading Over 7% Higher After Patent Ruling,2011-07-11 12:47:00-04:00,PDLI,neutral
992535.0,Nevada State Judge Denies Roche and Genentech's Motions to Dismiss PDL BioPharma's Complaint,2011-07-11 07:03:00-04:00,PDLI,negative
992536.0,PDL BioPharma Announces Retirement of $133.5M of 2.00% Convertible Senior Notes Due February 2012 ,2011-07-05 07:01:00-04:00,PDLI,neutral
992537.0,PDL BioPharma Revises Q2 2011 Revenue Guidance to $122M,2011-06-09 07:03:00-04:00,PDLI,neutral
992538.0,PDL BioPharma Announces Conversion Rate Adjustments for its Convertible Notes,2011-06-06 07:08:00-04:00,PDLI,neutral
992539.0,PDL BioPharma Provides Second Quarter 2011 Revenue Guidance of $128 Million vs $126 Million Estimate,2011-06-01 07:07:00-04:00,PDLI,neutral
992540.0,More Spying on Elite Funds - Part 2,2011-05-24 19:05:00-04:00,PDLI,neutral
992541.0,"PDL BioPharma Issues Redemption Notice for Its 2.00% Convertible Senior Notes Due February 15, 2012",2011-05-24 07:04:00-04:00,PDLI,neutral
992542.0,Short-Term Action Broke Through Resistance  05-10-2011,2011-05-10 19:21:00-04:00,PDLI,negative
992543.0,"Puts Purchased on PDL BioPharma, Inc. (PDLI)",2011-05-10 10:11:00-04:00,PDLI,neutral
992544.0,PDL BioPharma Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 (PDLI),2011-05-09 16:10:00-04:00,PDLI,neutral
992545.0,"Some High Dividend Paying Stocks For A Weak Market (MO, MRK, JNJ, NLY)",2011-03-16 15:59:00-04:00,PDLI,negative
992546.0,PDL BioPharma Sees Q1 Revenue of $83M,2011-03-07 07:20:00-05:00,PDLI,neutral
992547.0,PDL BioPharma Reports Q4 EPS of $0.20 vs. $0.21,2011-02-28 16:05:00-05:00,PDLI,neutral
992548.0,Options Brief: PDL BioPharma (PDLI),2011-02-28 10:44:00-05:00,PDLI,neutral
992549.0,PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final ,2011-02-28 07:28:00-05:00,PDLI,positive
992550.0,"Benzinga's Top Upgrades (FFIV, LLTC, PDLI, MU)",2011-01-20 08:21:00-05:00,PDLI,positive
992551.0,PDLI's Synagis Lawsuit Invalidated - Analyst Blog,2011-01-11 11:31:00-05:00,PDLI,negative
992552.0,PDLI's Synagis Lawsuit Invalidated - Analyst Blog,2011-01-11 10:45:00-05:00,PDLI,negative
992553.0,"Benzinga's Top Pre-Market NASDAQ Losers (STRA, COCO, APOL, PDLI)",2011-01-10 08:34:00-05:00,PDLI,negative
992554.0,Global Hunter Downgrades PDLI To Accumulate,2011-01-05 05:54:00-05:00,PDLI,neutral
992555.0,"Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio (PDLI, EXEL, SHP, VPHM)",2010-12-28 05:26:00-05:00,PDLI,negative
992556.0,A Peek Into The Market Before The Trading Starts,2010-12-01 08:09:00-05:00,PDLI,neutral
992557.0,PDL BioPharma Sees Fourth Quarter Revenue of $74M,2010-12-01 07:28:00-05:00,PDLI,neutral
992558.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,PDLI,positive
992559.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,PDLI,positive
992560.0,"PDLI Meets EPS, Beats on Top Line - Analyst Blog",2010-11-16 11:06:00-05:00,PDLI,positive
992561.0,J.P. Morgan Remains Uncertain on PDL BioPharma,2010-11-11 09:36:00-05:00,PDLI,negative
992562.0,PDL BioPharma Announces Third Quarter EPS of $.67,2010-11-10 16:04:00-05:00,PDLI,neutral
992563.0,A Peek Into The Market Before The Trading Starts,2010-10-04 07:54:00-04:00,PDLI,neutral
992564.0,PDL BioPharma Completes Special Dividend Payment,2010-10-04 07:36:00-04:00,PDLI,positive
992565.0,Oppenheimer's Current Biotech Ratings,2010-09-13 10:41:00-04:00,PDLI,neutral
992566.0,PDL BioPharma Provides Clarification Regarding Redemption of Convertible Subordinated Notes,2010-09-10 15:16:00-04:00,PDLI,neutral
992567.0,PDL BioPharma Announces Ex-Dividend Date of September 13 ,2010-09-09 07:20:00-04:00,PDLI,neutral
992568.0,PDLI Gives Third-Quarter Outlook - Analyst Blog,2010-09-03 08:36:00-04:00,PDLI,neutral
992569.0,Snap Commentaries From Oppenheimer,2010-09-02 11:02:00-04:00,PDLI,neutral
992570.0,"Benzinga’s Top Pre-Market NASDAQ Losers (JAZZ, SAFM, PDLI, COCO)",2010-08-23 08:50:00-04:00,PDLI,negative
992571.0,PDL BioPharma Down Hard On Patent Dispute (PDLI),2010-08-13 11:13:00-04:00,PDLI,negative
992572.0,"Benzinga’s Top Pre-Market NASDAQ Losers (PSTB, TSTC, PDLI, ARNA)",2010-08-13 09:22:00-04:00,PDLI,negative
992573.0,"Five High Dividend Yield Stocks (AGNC, CIM, NLY, PDLI, ANH)",2010-08-09 18:27:00-04:00,PDLI,neutral
992574.0,PDLI Matches Ests - Analyst Blog,2010-08-02 14:48:00-04:00,PDLI,neutral
992575.0,"Top 5 NASDAQ Stocks In The Biotechnology Industry With The Highest Profit Margins (QLTI, PDLI, TECH, GILD, AMGN)",2010-06-03 07:43:00-04:00,PDLI,positive
992576.0,"Top 5 Stocks In The Healthcare Sector With Lowest PEG (PDLI, PRX, MDCO, UTHR, CPIX)",2010-04-19 07:31:00-04:00,PDLI,negative
992577.0,"Top 5 Small-Cap NASDAQ Stocks with Lowest PEG Ratio (PDLI, SOLR, YONG, FEED, FUQI)",2010-04-01 06:23:00-04:00,PDLI,negative
992578.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,PDLI,positive
992579.0,"Top 5 Small-Cap NASDAQ Stocks with Lowest PEG Ratio (YONG, PDLI, HOGS, CMED, TRLG)",2010-02-10 03:47:00-05:00,PDLI,negative
992580.0,"Top 5 Small-Cap NASDAQ Stocks with Highest ROA (LPHI, RFMD CHKE, PDLI, YONG)",2010-02-10 03:45:00-05:00,PDLI,positive
992581.0,"Top 5 Small-Cap NASDAQ Stocks with Highest PEG Ratio (PDLI, CMED, HOGS, IIIN, YONG)",2009-12-24 07:27:00-05:00,PDLI,positive
992582.0,"Top 5 Small-Cap NASDAQ Stocks with Highest ROA (LPHI, CHKE, PDLI, YONG, CPSI)",2009-12-24 07:26:00-05:00,PDLI,positive
992583.0,"Top 5 Small-Cap NASDAQ Stocks with Lowest PEG Ratio (PDLI, CMED, IIIN, GLBL, HOGS)",2009-12-09 09:10:00-05:00,PDLI,negative
992584.0,"Benzinga’s Top Pre- Market Gainers (PDLI, NVAX, SIMG, ALTH, SEED, SQNM, VVUS)",2009-11-30 08:37:00-05:00,PDLI,positive
992585.0,"Top 5 Small-Cap Stocks with Best ROA (GNI, LPHI, PDLI, CHKE, PPD)",2009-11-30 08:09:00-05:00,PDLI,positive
992586.0,"Benzinga’s Top Pre- Market Losers (PDLI, DRAM, LIHR, ATPG, JDSU, SQNM, CHOP, ABIO)",2009-11-27 08:25:00-05:00,PDLI,negative
992587.0,"5 Stocks with Highest ROA and low PEG (LPHI, ESI, PDLI)",2009-10-30 07:28:00-04:00,PDLI,negative
992588.0,"PDL BioPharma Reports Q3 EPS Above View, Revenue Below Street View",2009-10-28 07:54:00-04:00,PDLI,neutral
992589.0,"PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction",2009-10-28 07:50:00-04:00,PDLI,positive
992590.0,"PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction (PDLI",2009-10-28 07:34:00-04:00,PDLI,positive
992591.0,"5 Stocks With Highest Operating Margin and PEG (AGO, NYB, KCAP)",2009-10-26 11:18:00-04:00,PDLI,neutral
992592.0,"5 Stocks with Highest ROA (LPHI, ESI, PDLI)",2009-10-22 01:37:00-04:00,PDLI,neutral
992593.0,"5 Stocks with Highest 5-Y Earnings Growth Estimate (CPY, ALSK, NCMI)",2009-10-20 02:37:00-04:00,PDLI,positive
992594.0,"5 Stocks with Highest Dividend Yield and PEG (KCAP, PSEC, GRT)",2009-10-08 13:00:00-04:00,PDLI,neutral
992595.0,"5 Stocks with Highest ROA and Lowest PEG (ESI, PDLI, ARO)",2009-10-06 02:04:00-04:00,PDLI,negative
992596.0,"5 NASDAQ Stocks with the Highest Dividend Yield and 52-week Decline (AINV, CPNO, KCAP)",2009-10-05 05:48:00-04:00,PDLI,neutral
992597.0,"WallStSense.com Fundamental & Technical Coverage of PMCS, FAST, CTSH, PDCO, GBCI and PDLI",2009-08-17 06:53:00-04:00,PDLI,neutral
992598.0,PDL BioPharma: High Dividend Biotech Stock,2009-08-17 05:43:00-04:00,PDLI,neutral
